Cavanagh Bethany J 4

What Happened

• Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics (BEAM), was granted a derivative award of 40,000 shares (reported as acquisition code "A") on 2026-01-31. The filing reports $0.00 per share for the grant (no cash paid at grant). This is an equity compensation award, not a purchase or sale of existing shares.

Key Details

• Transaction date: 2026-01-31 (Form 4 filed 2026-02-02 — appears timely).
• Transaction type/code: Award/Grant (A); reported as a derivative acquisition.
• Shares/options granted: 40,000 (reported price $0.00).
• Shares owned after transaction: Not specified in the supplied filing excerpt.
• Footnote: The award vests in equal monthly installments over the subsequent 48 months, subject to continued service with Beam.
• No indication the shares were exercised or sold immediately; this is a standard compensation grant.

Context

• This is a time‑based equity grant (stock option award) that will vest monthly over four years — it does not represent an immediate cash investment or disposition by the insider. Such grants are common for executive compensation and do not alone indicate a bullish or bearish signal.